Table 4. Network-based pathway enrichment analysis.
| regulator | # genes in the sub-network | Pathway | # pathway overlapping genes | p-value | Empirical p-value of DMD proximity analysis |
|---|---|---|---|---|---|
| TP53 | 83 | KEGG GLIOMA | 11 | 4.82E-10 | 0.513 |
| FOXO1 | 89 | KEGG PATHWAYS IN CANCER | 21 | 2.57E-09 | 0.11 |
| FOXO1 | 89 | BIOCARTA AMI PATHWAY | 7 | 8.23E-09 | 0.086 |
| EGR2 | 76 | BIOCARTA CREB PATHWAY | 7 | 2.55E-08 | 0.411 |
| FOXO3 | 74 | KEGG NEUROTROPHIN SIGNALING PATHWAY | 11 | 1.73E-07 | 0.035 |
| MEF2C | 98 | HALLMARK MYOGENESIS | 15 | 3.38E-07 | 0.312 |
| MYB | 87 | REACTOME HEMOSTASIS | 20 | 3.12E-06 | 0.549 |
| RBPJ | 63 | BIOCARTA BAD PATHWAY | 4 | 0.0001 | 0.276 |
| FOXO4 | 77 | REACTOME IMMUNE SYSTEM | 21 | 0.0028 | 0.481 |